Nanoparticles for Eye Injury from Chemical Exposure
DSP nanoparticles for treating nitrogen mustard induced corneal injury
['FUNDING_R21'] · VIRGINIA COMMONWEALTH UNIVERSITY · NIH-11096017
This research explores a new way to deliver medicine to the eye using tiny particles to help people who have suffered eye injuries from chemical agents like nitrogen mustard.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VIRGINIA COMMONWEALTH UNIVERSITY (nih funded) |
| Locations | 1 site (RICHMOND, UNITED STATES) |
| Trial ID | NIH-11096017 on ClinicalTrials.gov |
What this research studies
Exposure to certain chemicals, such as nitrogen mustard, can cause severe eye damage, including ulcers, cloudiness, and even blindness, and there isn't a good treatment yet. We are working on a new approach using tiny, biodegradable particles that can slowly release a common anti-inflammatory medicine, dexamethasone, directly into the eye. This sustained release could mean fewer eye drop applications, making treatment easier and more effective for patients. Our goal is to prevent serious complications like corneal ulcers and new blood vessel growth in the eye.
Who could benefit from this research
Good fit: This research is ultimately for patients who have experienced corneal injury due to exposure to chemical agents like nitrogen mustard.
Not a fit: Patients with other types of eye injuries or conditions not related to chemical exposure would likely not benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this approach could offer a long-lasting and more effective treatment for severe chemical-induced eye injuries, potentially preventing blindness and improving patient comfort.
How similar studies have performed: While dexamethasone eye drops have shown some benefit, their frequent application is a challenge, making this sustained-release nanoparticle delivery a novel approach to improve treatment.
Where this research is happening
RICHMOND, UNITED STATES
- VIRGINIA COMMONWEALTH UNIVERSITY — RICHMOND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: XU, QINGGUO — VIRGINIA COMMONWEALTH UNIVERSITY
- Study coordinator: XU, QINGGUO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.